石杉碱甲及奥拉西坦对老年血管性痴呆的疗效分析

Therapeutic efficacy of huperzine A and oxiracetam on senile vascular dementia

【目的】探讨石杉碱甲、奥拉西坦对老年血管性痴呆的长期疗效。【方法】选取66例血管性痴呆住院患者,随机分为对照组、石杉碱甲组、奥拉西坦组,每组22名患者。对照组:口服尼莫地平片40 mg/次,3次/d;石杉碱甲组:口服石杉碱甲片0.2mg/次,2次/d;奥拉西坦组,口服奥拉西坦胶囊800 mg/次,3次/d,三组均连续用药50周。分别在0、15及50周末进行简易精神状态量表(Minimum Mental State Examination,MMSE)和日常生活能力(Activities of daily living,ADL)量表测评。【结果】3组患者在治疗15及50周末其MMSE、ADL评分均明显提高补充具体数值,其中石杉碱甲组及奥拉西坦组均明显高于对照组,差异有统计学意义(P<0.05);石杉碱甲组与奥拉西坦组间比较无统计学差异(P>0.05)。【结论】石杉碱甲、奥拉西坦、尼莫地平对老年血管性痴呆均有明显疗效,石杉碱甲及奥拉西坦效果更佳,值得临床推广使用。

【Objective】To explore the long- term therapeutic efficacy of huperzine A and oxiracetam on senile vascular dementia.【Methods】A total of 66 inpatients with vascular dementia were randomly divided into three groups： control group, huperzine A group and oxiracetam group（n=22）. Patients in control group were orally given nimodipine tablets 40 mg tid; patients in huperzine A group were given huperzine A tablets 0.2mg bid in oral administration; patients in oxiracetam group were orally given oxiracetam capsules800 mg tid. All patients were continuously treated for 50 weeks. Mini-Mental Status Examination（MMSE） and Activities of Daily Living（ADL） were used to evaluate the patients on the pre-program, 15 th and 50 th weekends.【Results】The scores of MMSE and ADL in each group were improved significantly on the 15 th and 50 th weekend（P0.05）. The scores of MMSE and ADL in huperzine A group and oxiracetam group were significantly higher than those in control group（P0.05）. And there was no significant difference between huperzine A group and oxiracetam group（P0.05）.【Conclusion】Huperzine A, oxiracetam and nimodipine all have obvious therapeutic efficacy on senile vascular dementia. However huperzine A and oxiracetam are more effective and worth for clinical use.